SCHEMBL6350485

SCHEMBL6350485

COC(=O)N(CC(=O)c1ccccc1)C(C(=O)O)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.44
MEN1 O00255 4/20 0.41
KDM4E B2RXH2 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
CES1 P23141 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 5/20 0.40
POLB P06746 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
LMNA P02545 2/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 5/20 0.39
TSHR P16473 2/20 0.39
USP2 O75604 1/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350601 0.89 KMT2A (0.42) KMT2AMEN1KDM4ESMN1; SMN2MAPT
SCHEMBL6354396 0.86 ALDH1A1 (0.57) KMT2AMEN1KDM4ESMN1; SMN2MAPT
SCHEMBL6355870 0.84 ALDH1A1 (0.48) KMT2ASMN1; SMN2MAPTHPGDMAPK1
SCHEMBL6359362 0.84 TSHR (0.42) KMT2AMEN1KDM4ESMN1; SMN2MAPT
SCHEMBL6350978 0.84 ALDH1A1 (0.45) KMT2AMEN1KDM4ESMN1; SMN2MAPT
SCHEMBL6356051 0.84 ALDH1A1 (0.45) KMT2AMEN1KDM4ESMN1; SMN2MAPT
SCHEMBL6358298 0.84 TSHR (0.42) KMT2AMEN1KDM4ESMN1; SMN2MAPT
SCHEMBL6349361 0.84 ALDH1A1 (0.45) KMT2AMEN1KDM4ESMN1; SMN2MAPT
SCHEMBL6359182 0.83 KMT2A (0.39) KMT2AMEN1KDM4ESMN1; SMN2MAPT
SCHEMBL6347935 0.83 KMT2A (0.39) KMT2AMEN1KDM4ESMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 KMT2A 3612/4885MEN1 3756/4885KDM4E 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.